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Abstract
Background: Squamous cell carcinoma (SCC) of the skin is the most aggressive form of non-
melanoma skin cancer (NMSC), and is the single most commonly diagnosed cancer in the U.S., with
over one million new cases reported each year. Recent studies have revealed an oncogenic role of
activated signal transducer and activator of transcription 3 (Stat3) in many human tumors, especially
in those of epithelial origin, including skin SCC. Stat3 is a mediator of numerous growth factor and
cytokine signaling pathways, all of which activate it through phosphorylation of tyrosine 705.
Results: To further address the role of Stat3 in skin SCC tumorigenesis, we have analyzed a panel
of human skin-derived cell lines ranging from normal human epidermal keratinocytes (NHEK), to
non-tumorigenic transformed skin cells (HaCaT), to highly tumorigenic cells (SRB1-m7 and SRB12-
p9) and observed a positive correlation between Stat3 phosphorylation and SCC malignancy. We
next determined the role of Stat3 activity in cell proliferation and viability under serum-free culture
conditions. This was accomplished by suppressing Stat3 activity in the SRB12-p9 cells through stable
expression of a dominant negative acting form of Stat3β, which contains a tyrosine 705 to
phenylalanine mutation (S3DN). The S3DN cells behaved similar to parental SRB12-p9 cells when
cultured in optimal growth conditions, in the presence of 10% fetal calf serum. However, unlike the
SRB12-p9 cells, S3DN cells underwent apoptotic cell death when cultured in serum-free medium
(SFM). This was evidenced by multiple criteria, including accumulation of sub-G1 particles, induced
PARP cleavage, and acquisition of the characteristic morphological changes associated with
apoptosis.
Conclusion: This study provides direct evidence for a role for Stat3 in maintaining cell survival in
the conditions of exogenous growth factor deprivation produced by culture in SFM. We also
propose that delivery of the S3DN gene or protein to tumor cells could induce apoptosis and/or
sensitize those cells to the apoptotic effects of cancer therapeutic agents, raising the possibility of
using S3DN as an adjunct for treatment of skin SCC.
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Introduction
Non-melanoma skin cancer (NMSC) is the most common
cancer in the U.S., with over a million new cases of the two
most common forms, squamous and basal cell carci-
noma, anticipated in 2004 [1]. The more clinically aggres-
sive form, squamous cell carcinoma (SCC) [2], has been
increasing in incidence since the 1960s at annual rates
from 4% to as much as 10% in recent years [3]. About
95% of skin SCC cases are diagnosed at an early stage and
are easily controlled. Unlike early stage SCC, advanced
SCC is aggressive, often resistant to local therapy, requires
repeated surgical resections and courses of radiotherapy,
and accounts for approximately 2000 U.S. deaths each
year [1,4]. Advanced disease- and treatment-related mor-
bidity have a profound impact on patients' quality of life,
frequently producing cosmetic deformity, loss of func-
tion, and psychosocial problems. Improved control of
advanced skin SCC is clearly necessary and will rely on a
thorough understanding of the molecular basis for skin
SCC progression.
Signal transducers and activators of transcription (Stat)
proteins, a family of latent cytoplasmic transcription fac-
tors, are expressed in many cell types and, in response to
a wide variety of extracellular polypeptides, regulate the
transcription of a broad spectrum of genes that are criti-
cally involved in cytokine signaling [5], cell proliferation
and development [6], and tumorigenesis [7-9]. Upon
binding of extracellular ligands, cell surface receptors oli-
gomerize and activate associated Janus kinases (JAKs),
which in turn phosphorylate Stats on a single critical tyro-
sine residue located adjacent to an -SH2 (src homology
domain 2) domain. The Stats then dimerize via reciprocal
-SH2 domain phosphorylation site interactions and trans-
locate to the nucleus where they regulate gene expression
by direct DNA binding or by associating with other tran-
scription factors [10,11]. The activity of Stats can be abol-
ished by mutation of this critical tyrosine [12,13].
Among the seven known members of mammalian Stat
family, Stat3 has been most strongly implicated in tumor-
igenesis [7-9]. Elevated levels of Stat3 activity have been
observed in a number of human cancers and cancer cell
lines [9]. In cancers of epithelial origin, Stat3 is constitu-
tively activated in head and neck squamous cell carci-
noma (HNSCC) [14,15], breast cancer cell lines [16,17],
ovarian cancer cell lines [18], and lung cancer cell lines
[19]. In particular, Stat3 plays a critical role in the devel-
opment of skin cancer [20]. In an experimental two-stage
mouse skin chemical carcinogenesis model it has been
shown that Stat3 is constitutively activated in skin tumors
[21], and that activated Stat3 is indispensable for both the
initiation and the promotion stages of epithelial carcino-
genesis [22]. The critical role of Stat3 in skin tumor devel-
opment was further supported by data obtained from a
transgenic mouse model in which a constitutively active
mutant of Stat3 called Stat3C (7), was expressed in skin
under the control of the keratin-5 promoter [23]. These
mice have a skin phenotype closely resembling psoriasis
in humans and, when subjected to the two-stage skin
chemical carcinogenesis protocol, rapidly developed car-
cinomas, bypassing the papilloma stage that normally
takes place in this model [[23], Chan et al, submitted].
Apoptosis or programmed cell death, is mediated through
two major pathways, the extrinsic and intrinsic [24,25].
The extrinsic pathway is primarily triggered by the binding
of extra-cellular death ligands (e.g. TNFα, TRAIL and FasL)
to their cognate membrane death receptors. The intrinsic
pathway is often initiated by cellular stresses such as with-
drawal of survival factors, direct DNA damage (e.g. UV
exposure, cytotoxic drugs), and is characterized by the dis-
ruption of mitochondrial membrane integrity, an event
regulated by Bcl-2 protein family members [26,27]. There
are more than 20 known members of the Bcl-2 family
which, based on their functions in regulating apoptosis,
can be divided into an anti-apoptotic 'Bcl-2-like' group,
(Bcl-2, Bcl-XL, Bcl-w, Bfl-1/A1 and Mcl-1 etc) and a pro-
apoptotic group (Bax, Bak, Bok, Bcl-Xs, Bad, Bid, Bik/Nbk,
Bim, Hrk, Bmf, Noxa and Puma etc). It has been reported
that Stat3 can regulate transcription of several Bcl-2 family
proteins, such as Bcl-2 and Bcl-xL [28-31], Bax [32], and
Mcl-1 [33-35].
At early stages of tumor development, tumor cells often
have to face and survive harsh physiological micro-envi-
ronments, such as lack of nutrition and/or blood supply,
survival factor insufficiency, and hypoxia, which generally
lead to apoptosis in normal cells [36]. In fact, it has been
well accepted that one of the six hallmarks of tumor cells
is the reduced or complete loss of dependence on exoge-
nous growth factor stimulation for survival and prolifera-
tion [37]. Stats are the first family of transcription factors
found to be directly activated upon growth factor receptor
stimulation. Stat3 is thought to confer protection against
apoptosis in many transformed or tumor cells. Several
studies in which Stat3 activity is either blocked by anti-
sense oligonucleotides, small interfering RNA or expres-
sion of dominant negative Stat3 isoforms [14,32,38-40],
or elevated by expression of Stat3C [41], have shown an
inverse correlation between Stat3 activity and induced
apoptosis.
In this study we have examined the activity of Stat3 in sev-
eral human skin-derived cell lines, ranging from non-
transformed to highly malignant, and observed a positive
correlation between malignancy and constitutive Stat3
phosphorylation. In addition, we have generated human
skin SCC cell lines with reduced Stat3 activity by stably
expressing a dominant negative acting form of Stat3β,Molecular Cancer 2006, 5:15 http://www.molecular-cancer.com/content/5/1/15
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Stat3 phosphorylation correlates with human skin SCC malignancy Figure 1
Stat3 phosphorylation correlates with human skin SCC malignancy. NHEK cells were grown for 48 hours in KGM-2 growth 
media and HaCaT, SRB12-p9 and SRB1-m7 cells were grown for 48 hours in normal growth media containing 0.5% serum, fol-
lowed by culture for 2 hours in SFM and then treated for 30 min with 100 IU/ml IFN-α. Whole cell extracts were purified, sub-
jected to Western blotting and sequentially probed with antibodies specific to Stat3α, tyrosine 705 phosphorylated Stat3α 
(Stat3-p) (middle panel), and β-actin as a control for well loading.
NHEK  HaCaT    -m7       -p9   
SRB1  SRB12
IFN-A      -    +     -     +     -     +     -     +
Stat3A
Stat3-p 
B-actin 
-97
-68
-97
-68
-43Molecular Cancer 2006, 5:15 http://www.molecular-cancer.com/content/5/1/15
Page 4 of 13
(page number not for citation purposes)
Establishment of cell clones stably expressing S3DN and S3WT proteins Figure 2
Establishment of cell clones stably expressing S3DN and S3WT proteins. (A) SRB12-p9 cells were transfected with expression 
vectors as described in materials and methods. Whole cell extracts from cell clones (number shown above each lane) were 
subjected to Western blotting and probed sequentially with antibodies to the FLAG octapeptide, Stat3 (recognizing both α and 
β isoforms), and β-actin. (B) SRB12-p9, Neo, S3DN2 and S3WT6 cells (lane 1, 2, 3 and 4 respectively) were serum-starved for 
2 days. Nuclear extracts were prepared and the EMSA assay was performed as described in Materials and Methods. In lane 5 
nuclear extract from S3WT6 was pre-incubated with excess cold (unlabeled) Stat3 probe prior to the addition of labeled 
probe. Open arrow, expected location for Stat3α homodimer; closed arrow, unbound probe; dot, non-specific band. Results 
are representative of three separate experiments.
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hereafter referred to as S3DN [42-44]. The S3DN cells,
unlike the parental SRB12-p9 cells, undergo apoptosis in
the conditions of exogenous growth factor deprivation
produced by culture in serum free medium (SFM).
Results
Constitutive phosphorylation of Stat3 positively correlates 
with malignancy of human skin SCC cell lines
Stat3 transcriptional activity can be induced by the phos-
phorylation of a single tyrosine residue (Tyr705) by recep-
tor associated Janus kinases. Increased Stat3 activation is
often associated with either elevated constitutive levels of
Stat3 protein or increased Stat3 tyrosine phosphorylation
[14]. To further elucidate the role of Stat3 in skin cancer
development, we first examined the Stat3 status in
NHEKs, non-tumorigenic, spontaneously transformed
keratinocyte cells (HaCaT) and two aggressive skin SCC
cell lines (SRB1-m7 and SRB12-p9). In order to avoid
detecting a high level of background Stat3 phosphoryla-
tion, the HaCaT and SRB cells were switched from their
normal growth in medium which contains 5 and 10%
FCS, respectively, to medium containing 0.5% serum for
two days, followed by an additional two hours culture in
SFM. We have previously reported that low concentra-
tions of IFN-α efficiently induce Stat3 phosphorylation in
SRB12-p9 cells [45]. In order to compare the inducibility
of Stat3 phosphorylation between normal, premalignant
and malignant skin cells, they were treated with 100 inter-
national units (IU)/ml IFN-α for 30 min, and then whole
cell protein was extracted and subjected to western blot
probing with a Stat3α- or a Stat3 phospho-tyrosine 705-
specific antibody. All cell lines expressed comparable
steady state levels of Stat3α protein with or without IFN-
α treatment (Fig. 1, upper panel). However, in the absence
of IFN-α treatment, phosphorylated Stat3α (phospho-
Stat3α) was only observed in the tumorigenic skin SCC
cell lines (Fig. 1, lanes labeled SRB1-m7 and SRB12-p9,
middle panel). Treatment with IFN-α, which has been
previously shown to induce Stat3 phosphorylation and
DNA binding [44], induced phosphorylation in the
HaCaT cells, but not in the NHEK cells (Fig. 1 middle pan-
els, NHEK and HaCaT lanes). The upper band in lanes 3–
5 is non-specific and is sometimes observed with this
antibody.
Establishment of cell lines stably expressing a dominant 
negative form of Stat3 (S3DN)
To explore the role of Stat3 in skin cell malignancy, we
over-expressed both the wild type Stat3α and a dominant
negative form of Stat3β in one of the tumorigenic SCC cell
lines, SRB12-p9. It has been reported that Stat3β, a natu-
rally occurring Stat3 splice variant that has a truncated C-
terminus, can function as a dominant negative form of
Stat3 and inhibit its transcriptional activity [42,43]. It was
subsequently shown that substituting the critical Jak
kinase tyrosine phosphorylation site with phenylananine
generated a form of Stat3 that could block DNA binding
by all endogenous forms of Stat3 (Stat3β-Y705F) [44]. We
established SRB12-p9 cell clones expressing either the
FLAG-tagged wild type Stat3α protein (S3WT) or FLAG-
tagged Stat3β-Y705F (S3DN) (Fig. 2A). Over-expressing
the S3WT resulted in higher Stat3 DNA binding activity
than in parental cells as determined by EMSA (Fig. 2B,
compare lane 4 with lane 1, white triangle), while the
DNA binding activity in cells expressing the S3DN was
reduced (Fig. 2B, compare lane 3 to lanes 1 and 2). The
specificity of DNA binding was confirmed by the elimina-
tion of the shifted band upon addition of excess unla-
belled Stat3 probe (Fig. 2B, compare lane 5 with lane 4).
We note that the EMSA band intensities in Fig. 2B are
lower than those typically detected for lysates of cells tran-
siently transfected with expression constructs for Stats (see
[44]). In the present study we assayed for endogenous and
stably expressed Stat3 isoforms, which are less abundant
than in transiently transfected cells.
Stat3 activity is required for cell survival in SFM
Stressful physiological conditions, such as a shortage of
nutrients or growth factors, often result in apoptotic cell
death in non-transformed cells but not in transformed
cells. The S3WT and S3DN cell lines allowed determina-
tion of the role of Stat3 on cell viability during culture in
SFM, a well-established experimental stress condition.
Cells were grown in the presence or absence of FCS for 4
days and cell viability measured by the MTT assay at 1 day
intervals. Doubling times for cells growing at a subconflu-
ent density (between days 1 and 3) were calculated based
on the viability data shown in Fig. 3A. In the standard
10% FCS-containing medium there was no major differ-
ence in the cell viability and calculated doubling times for
parental SRB12-p9 cells and control SRB12-p9 cells stably
transfected with the empty pSG5 expression vector and
the pKJ1 neomycin resistance vector (Neo) (Fig. 3A, black
bars and Table 1). The S3WT cells (represented by clones
6 and 10) had an increase in doubling time of approxi-
mately 2 hours and one of the S3DN cell lines (S3DN5)
was increased by 3 hours, indicating no correlation
between Stat3 expression pattern and doubling time in
standard media (Fig. 3A and Table 1). However, in SFM
(Fig. 3A, white bars) the two S3DN cell lines showed no
increase in cell number between days 2 and 3 and by the
4th day had a reduction in cell viability, indicating cell
death. Visual inspection revealed that S3DN cells cultured
in SFM became rounded and detached from the plate, two
events that typically accompany apoptotic cell death (Fig.
3B, compare upper and lower S3DN2 panels). In contrast,
the SRB12-P9, Neo and S3WT cells showed only a slight
reduction in cell viability compared to cells grown in FCS-
containing medium (Fig. 3A compare white bars to black
bars and table 1). From this data we conclude that Stat3Molecular Cancer 2006, 5:15 http://www.molecular-cancer.com/content/5/1/15
Page 6 of 13
(page number not for citation purposes)
Stat3 activity is required for survival in SFM Figure 3
Stat3 activity is required for survival in SFM. (A) SRB12-p9, Neo and two representative independent S3WT (S3WT6, 
S3WT10) and S3DN clones (S3DN2, S3DN5) were cultured for the indicated times in 10% FCS-containing media or SFM and 
cell viability was determined by the MTT assay (see materials and methods). White and black bars indicate the mean absorb-
ance at 540 nm for cells grown in SFM or 10% FCS-containing media, respectively. Error bars indicate SEM for triplicate cul-
tures. Results shown are representative of >4 assays that included 2 independent S3WT and S3DN cell clones. (B) SRB12-p9, 
Neo, S3DN2 and S3WT6 cells were cultured for 5 days in 10% FCS-containing media or SFM (upper and lower rows, respec-
tively). Results shown are representative of 3 independent S3DN and S3WT cell clones from 4 separate experiments. Cells 
were photographed on a phase contrast microscope (100×).
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activity is required for SCC cell survival in SFM. This
response was consistently observed for SRB12-p9 cells
and multiple independent Neo (n = 2), S3DN (n = 3) and
S3WT (n = 3) cell clones, for 4 experiments.
Expression of S3DN protein causes apoptosis in cells 
grown in SFM
The reduced viability of the S3DN cells grown in SFM
could be due to either cell death alone or to a combina-
tion of cell death and reduced proliferation. There is
abundant evidence for a role for Stat3 both in regulating
proliferation and in suppressing apoptotic cell death [7-
9]. In order to determine whether expression of the S3DN
or S3WT proteins could also influence proliferation, we
compared the cell cycle profiles of the SRB12-p9, Neo,
S3DN and S3WT cells. Cells were cultured under condi-
tions identical to that shown in Fig. 3B and their cell cycle
profiles determined by flow cytometry. In FCS-containing
media all cell populations had similar percentages in the
G1, S and G2 phases of the cell cycle (Fig. 4A, upper pan-
els). When grown in SFM for 4 days several small differ-
ences were observed. SRB12-P9, S3DN2 and S3WT6 cells
showed reductions in the percentage of cells in S phase,
the S3DN2 cells showed an increase in the percentage
of cells in the G2 phase, and SRB12-P9 and S3WT6 cells
showed an increase in the percentage of cells in the G1
phase (Fig. 4A, -FCS panels). However the most promi-
nent difference was the greater number of DNA contain-
ing particles in the sub-G1 size range observed for the
S3DN2 cells in both FCS-containing media (12% of total
particle count compared to approximately 5% for the
other cell lines) and in SFM (28.5% compared to 2–3%
for the other cells, Fig 4A). The presence of sub-G1 parti-
cles is a hallmark of apoptosis for cultured cells. This find-
ing was reproducible for multiple Neo, S3DN and S3WT
cell clones and is consistent with the results shown in Fig.
3A and 3B, strongly suggesting that S3DN expression pri-
marily affects the control of apoptosis and not prolifera-
tion in this model.
In order to further confirm that the loss of cell viability of
the S3DN cells grown in SFM is due to increased apopto-
sis, we assayed for the appearance of c-PARP protein, the
cleaved from of PARP, in cells treated as in Fig. 4A. PARP
cleavage facilitates irreversible cellular disassembly and
provides a highly sensitive indicator of apoptosis [46].
The appearance of c-PARP was most pronounced in the
S3DN2 cells grown in SFM, as determined by western
blotting with a c-PARP-specific antibody (Fig. 4B, upper
panel). A low level of c-PARP was detectable in S3DN2
cells grown in FCS-containing media, as well as in Neo
and S3WT6 cells grown in SFM (Fig. 4B, upper panel).
It has been reported in other cell culture systems and ani-
mal models that Stat3 regulates apoptosis via modulation
of transcription of several of the Bcl-2 family proteins,
including Bcl-2, Bcl-xL, Bax and Mcl-1 [28-35]. Here we
observe enhanced Bax protein expression for S3DN2
grown in SFM, but not for the other cells, suggesting a pos-
sible role for Bax in this apoptotic effect (Fig. 4B, middle
panel). As in 4A, these results are representative of several
Neo, S3DN and S3WT cell clones in at least 2 independent
experiments per clone.
Discussion
Elevated Stat3 activity has been observed in numerous
spontaneous and experimentally established mammalian
cancers, demonstrating a critical role in tumorigenesis [7-
9,17]. In this study we provide direct evidence that Stat3
activity, as indicated by phosphorylation at tyrosine 705,
positively correlates with malignancy in human skin-
derived cell lines. Suppression of Stat3 activity, through
forced expression of the S3DN protein, in human skin
SCC cells blocks their growth factor- and/or other serum
factor-independence, a major characteristic of malig-
nancy.
Recent studies have provided convincing evidence for a
critical role for Stat3 in every stage of mouse skin cancer
development, from promoting the survival of initiated
cells to conferring late-stage malignant characteristics
Table 1: Expression of wild type Stat3α (S3WT column) and dominant negative Stat3β (S3DN column) protein does not correlate with 
cell doubling time. Cell doubling time was calculated as described in Materials and Methods using the proliferation data shown in Fig. 
3A. + symbol refers to the approximate level of S3WT or S3DN protein, as determined by Western blotting. N/A: not applicable.
Doubling Time
Cell line Relative protein level Day 1 through Day 3 ime
S3WT S3DN 10% FCS -FCS
SRB12-p9 + - 15.6 18.6
P9 neo + - 15.4 17.9
S3DN2 + ++ 15.3 N/A
S3DN5 + ++ 18.4 N/A
S3WT6 +++ - 17.4 20
S3WT10 + - 17.4 18.6Molecular Cancer 2006, 5:15 http://www.molecular-cancer.com/content/5/1/15
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Expression of S3DN protein leads to apoptosis in SFM Figure 4
Expression of S3DN protein leads to apoptosis in SFM. SRB12-p9, Neo, S3DN2 and S3WT6 cells were cultured in 10% FCS-
containing media or SFM for 4 days. (A) Cells and floating material were collected, fixed in 70% ethanol, stained with propidium 
iodide and analyzed by flow cytometry. The percentage of cells in the G1/0, S and G2 phases of the cell cycle are indicated for 
each cell line and treatment condition. Numbers to the left of the G1/0 peak indicate the percentage of sub-G1/0 particles 
from the total population of gate particles (excluding clumped cells). (B) Whole cell extracts were resolved on an SDS polyacr-
ylamide gel, transferred to nitrocellulose and sequentially probed with antibodies specific for c-PARP, Bax and β-actin. Results 
shown in A and B are representative of 2 Neo and 3 S3DN and S3WT clones, in 2 independent experiments.
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such as enhanced motility and invasiveness [21,22]. In
parallel with these studies we sought to develop a human
skin SCC model in which Stat3 activity is stably sup-
pressed, in order to assess the contribution of activated
Stat3 to the malignant phenotype in human disease. The
SRB12-p9 cell line was originally derived from an aggres-
sive skin SCC tumor. These cells were chosen for stable
transfection of the S3DN protein because, in addition to
having constitutive and IFN-α inducible Stat3 phosphor-
ylation, they are highly tumorigenic upon subcutaneous
injection into nude mice and can be readily transfected
and selected for stable gene expression [45].
The S3DN protein is a unique Stat3 blocking reagent. It
consists of Stat3β, τhe short alternative splice product of
the Stat3 gene, bearing a point mutation at the critical
tyrosine 705 phosphorylation site [44], that has been
FLAG-tagged to allow distinguishing it from the endog-
enous Stat3β. Stat3β was previously shown to act in a
dominant negative manner to suppress the transcriptional
activity of Stat3α [42]. However Stat3β can be transcrip-
tionally active under conditions where Stat3α is not,
through interaction with the N-terminal segment of c-jun,
[43]. Unlike Stat3β, the S3DN protein lacks detectable
DNA binding or transcriptional activity in EMSA and tran-
sient transfection reporter assays, respectively [44], and
would therefore not be expected to induce Stat3β-specific
effects. The S3DN protein should be able to form non-
functional heterodimers with endogenous forms of
Stat3α or β however, blocking their ability to enter the
nucleus and/or bind DNA. Alternatively, S3DN may inter-
fere with endogenous Stat3 activity at another level, such
as the phosphorylation by JAK kinases, where S3DN may
occupy the Stat3 docking sites on the cytoplasmic
domains of growth factor and cytokine receptors, thereby
blocking phosphorylation of endogenous Stat3α. This
later possibility is less likely since we do not observe a
reduced level of phospho-Stat3α in the S3DN cells com-
pared to SRB12-p9 or Neo cells (data not shown). Also,
recent evidence has emerged indicating that unphosphor-
ylated Stat3α can drive expression of several genes, includ-
ing some well known oncoproteins, through a novel
mechanism that is distinct from that of phosphorylated
Stat3α [47]. It therefore cannot be formally ruled out that
S3DN, even though it cannot be phosphorylated, could
itself have effects not involving interaction with endog-
enous Stats.
Although the precise mechanism of suppression of Stat3
activity by S3DN is unclear, its expression in the SRB12-p9
cells reduced binding of Stat3α to DNA (Fig. 2B) and was
predicted to inhibit the constitutive Stat3 activity, thereby
suppressing proliferation and possibly de-repressing
apoptotic signals. To our surprise, the initial characteriza-
tion of the S3DN stable transfectants indicated no obvi-
ous effects on proliferation rate or viability compared to
the parental SRB12-p9 cells (Table 1). Similarly, forced
overexpression of the S3WT protein did not produce an
increase in proliferation rate, but rather the opposite
occurred, with an approximately 2 hour increase in cell
doubling time observed for 2 of the S3WT clones (Table
1). While this latter result is difficult to explain, the very
short doubling time for SRB12-p9 cells (15–16 hours)
suggests that further increases in proliferation rate may be
limited by other intrinsic factors such as nutrient and bio-
molecule availability. The lack of consistent reduction in
cell proliferation rate for the S3DN cells could be
explained by an insufficient amount of S3DN protein
expression necessary to block endogenous Stat3α activity
under these culture conditions. The highest expressing
S3DN clone, S3DN5, shows approximately equal signal
for the Stat3 α and β bands, indicating roughly equal
amounts of both proteins (Fig. 2A, middle panel, lanes
labeled S3DN2 and 5). While this is a substantial increase
over the wild type amount of Stat3β protein (compare lev-
els of Stat3β between S3DN and S3WT cells in Fig. 2A,
middle panel), it appears insufficient to illicit the effects
on cell proliferation and/or cell viability that would be
consistent with a suppression of endogenous Stat3α activ-
ity.
In an attempt to determine whether expression of S3DN
could affect any Stat3α regulated cellular processes, we
grew the cells in SFM, an experimental stress condition
known to suppress cell growth and induce apoptosis in
many cell lines. Indeed, it was only after depriving the
S3DN cells of FCS that a dramatic effect was observed.
Several independently selected S3DN clones underwent
cell death induction when grown in SFM, which was not
observed with SRB12-p9, Neo or S3WT clones. This effect
was characterized by cell rounding and detachment from
the plate followed by disintegration into subcellular parti-
cles, all characteristics of apoptotic cell death. This effect
was quantified using the MTT cell viability assay. A reduc-
tion in cell viability for the S3DN cell lines after 2 days in
SFM indicated that cell death was induced, in addition to
a possible reduction in proliferation rate. In contrast, the
SRB12-p9 and Neo cells remained viable and continued
to proliferate, with only an approximately 2–3 hour
increase in doubling time.
The induction of cell death could entirely account for the
reduced viability of S3DN cells grown in SFM. However,
because Stat3 is also a key regulator of cell proliferation
[7-9], reduced proliferation may also contribute to this
effect. Comparison of the cell cycle profiles of SRB12-p9,
Neo, S3DN and S3WT cells indicated that, in FCS-contain-
ing media, the distribution of cells in the G1/0, S and G2
phases of the cell cycle was similar in all cases. One excep-
tion was the higher amount of sub-G1 DNA-containingMolecular Cancer 2006, 5:15 http://www.molecular-cancer.com/content/5/1/15
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particles for the S3DN2 cell line than for the other cell
lines (12% compared to approximately 5% for the other
cell lines, Fig. 4A upper row), suggesting a higher rate of
apoptosis even in the presence of 10% FCS. Four days of
culture in SFM resulted in an increase to 28.5% sub-G1
particles for the S3DN2 cells, but not the other cell lines.
It should be noted that the data in the S3DN2 -FCS panel
represents the relatively small population of S3DN2 cells
remaining alive after 4 days in SFM (see corresponding
panels in Fig. 3B). Surprisingly, these cells still exhibited a
similar percentage of cells in the G1/0 phase to those
growing in FCS-containing media, indicating that S3DN
expression induces cell death, but does not cause an accu-
mulation of cells in G1/0. However there was a reduction
in the percent of cells in S phase with a proportional
increase in the G2 fraction for the S3DN2 cells in SFM,
indicating potential blocks at both the G1 to S phase tran-
sition and at mitosis. Thus the contribution of reduced
proliferation to the overall effect of the S3DN expression
on these cells is minor compared to the apoptotic effect.
This conclusion is further supported by our finding that
the pro-apoptotic Bcl-2 family member, Bax, is upregu-
lated in the S3DN cells grown in SFM and this effect is
accompanied by accumulation of c-PARP.
The results of the present study are consistent with an anti-
apoptotic role for Stat3 in human skin SCC and are also
in agreement with much of the predicted role for Stat3
derived from recent mouse skin tumorigenesis studies
[21-23]. In addition, it has been demonstrated that gene
therapy with Stat3β was effective in suppressing tumor
growth in an in-vivo mouse melanoma model [40]. This
effect was associated with induction of the secreted death
ligand TRAIL, which could induce apoptosis and cell cycle
arrest of adjacent non-transfected cells [48]. Other inves-
tigators, using a complimentary approach to assessing
Stat3 function, have demonstrated that expression of the
constitutively active Stat3C protein in fibroblasts can pro-
tect them from UV-induced apoptosis [41].
Conclusion
We have demonstrated that suppression of Stat3 signaling
through forced expression of the S3DN protein in human
skin SCC cells blocks their growth factor- and/or other
serum factor-independence. Unlike the parental SRB12-
p9 cells, the S3DN cells remain viable only when cultured
under optimal growth conditions, in nutrient medium
supplemented with 10% FCS. The SFM culture condition
is likely to provide a closer approximation to the inhospi-
table conditions found in tumor microenvironments in-
vivo. This raises the exciting possibility of using S3DN as
an adjunct therapy for treatment of skin SCC. We propose
that delivery of the S3DN gene or protein to tumor cells
could induce apoptosis directly and/or sensitize tumor
cells to the apoptosis-inducing effects of cancer therapeu-
tic agents. Future studies are planned to explore this pos-
sibility. These include assessing the effect of S3DN
expression in in-vivo tumor models. We will begin by com-
paring the malignant properties of the S3DN cells with
Neo control cells in mouse subcutaneous injection tumor-
igenicity assays. This study, together with our in-vivo stud-
ies in mouse skin, supports the hypothesis that Stat3 is a
central regulator of apoptosis and proliferation in malig-
nant skin cells.
Methods
Cell culture and generation of stable S3DN expressing 
SRB12-p9 cell lines
The origin and culture of the human skin SCC cell line
SRB12-p9 was described previously [45]. HaCaT cells
were cultured according to [49] in Dulbecco's Modified
Eagles Media (DMEM)-low glucose media, supplemented
with 5% fetal calf serum (FCS). Normal human epidermal
keratinocytes (NHEK) cells were purchased from Clonet-
ics (now Cambrex BioScience, Walkersville, MD) and
grown in KGM-2 media (Cambrex) supplemented with
hEGF (0.1 ng/ml), insulin (5.0 µg/ml), hydrocortisone
(0.5 µg/ml, calcium (0.15 mM), epinephrine (5 ng/ml),
transferrin (10 µg/ml), Gentamycin (50 µg/ml), Ampho-
tericin-B (50 ng/ml) and 2 ml bovine pituitary extract. All
cells were grown in a humidified atmosphere with a 5%
CO2 concentration.
The pSG5-Stat3β-Y705F-FLAG expression vector was con-
structed by ligating the mouse Stat3β-Y705F cDNA cas-
sette into the EcoRI site of the pSG5 expression vector
[50], followed by sequential PCR-based site-specific
mutagenesis using the following oligonucleotides: 5'-
TCATTGATGCAGTTTGGAAACTCGAGTAACACTCTGT-
GAGCTGATA-3' and 5'-TATCAGCTCACAGAGTGT-
TACTCGAGTTTCCAAACTGCATCAATGA-3', to introduce
an Xho I site immediately upstream of the stop codon at
position 723. The FLAG epitope extension was created by
inserting a DNA fragment, consisting of the following
complimentary oligonucleotide pair: 5'-TCGAAGACTA-
CAAAGACGATGACGATAAATAGTAGTGATGACTTGT-
CATCATCGTCCTTATAATCAGATCTT-3' and 5'-
TCGAAAGATCTGATTATAAGGACGATGATGACAAGTCA
TCACTACTATTTATCGTCATCGTCTTTGTAGTCT-3', into
the newly generated Xho I site. The pSG5-Stat3α-FLAG
plasmid was constructed by ligating the mouse Stat3α cas-
sette into the EcoRI site of the pSG5 expression vector, fol-
lowed by sequential PCR-based site-specific mutagenesis
using the following oligonucleotides: 5'-
CTTCTGGTTTCAGCTCCTCGAGCATGGGGGAGGTAG-
CACACT-3' and 5'-AGTGTGCTACCTCCCCCATGCTC-
GAGGAGCTGAAACCAGAAG-3', to introduce an Xho I
site immediately upstream of the stop codon. The FLAG
epitope extension was created by inserting the same com-
plimentary oligonucleotide pair used for the Stat3β con-Molecular Cancer 2006, 5:15 http://www.molecular-cancer.com/content/5/1/15
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struct. The Stat3β-Y705F and Stat3α cDNA cassettes were
a gift from T. Schaefer (Meso Scale Discovery). The result-
ing plasmids were linearized with Aat II restriction
enzyme and electroporated along with the bacterial neo-
mycin phosphotransferase gene expression vector pKJ1
[51], and stably expressing cell clones were isolated essen-
tially as previously described [45]. 5 × 106 cells suspended
in 800 µl PBS were electroporated with 5 µg of linearized,
purified pSG5-Stat3β-Y705F-FLAG or pSG5-Stat3α-FLAG
and 0.5 µg pKJ1 with a Bio-Rad Gene Pulser set at 200 V
and 960 µF. Cells were then plated at a density of approx-
imately 1 × 106 cells/10 cm culture plate, and after 24 h
subjected to neomycin selection (300 µg/ml G418 sulfate,
GIBCO/BRL, Rockville, MD) for up to 14 days. Individual
colonies were isolated, propagated, and divided into two
aliquots, one for freezing and the other for expansion and
western blotting.
Reagents
Recombinant human interferon alpha (IFN-α) was pur-
chased from Serotec Inc. (Raleigh, NC). Antibodies
against human Stat3, Stat3 phospho-tyrosine 705, and
human β-actin were supplied by Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Antibodies specific for Bax, cleaved
poly [ADP-ribose] polymerase (PARP) were purchased
from Cell Signaling Technology (Beverly, MA). Antibody
against the FLAG epitope was from Sigma-Aldrich (St.
Louis, MO).
Western blotting and electrophoretic mobility shift assay 
(EMSA)
Whole cell extract purification from stably transfected
cells and western blotting was performed as described pre-
viously [45], with minor modifications. Total cellular pro-
tein was prepared using RIPA lysis buffer (150 mM NaCl,
10 mM Tris-HCl pH 7.5, 1 mM EDTA, 1% NP-40, 1 mM
dithiothreitol) supplemented with Complete protease
inhibitor cocktail (Roche, Indianapolis, IN) according to
manufacturer-provided instructions. Extracted protein
was quantified using the Bio-Rad Protein Assay kit (Her-
cules, CA). Proteins were separated by SDS acrylamide gel
electrophoresis and transferred to nitrocellulose mem-
branes (Schleicher & Schuell, Dassel, Germany). Blots
were blocked with 5% milk powder for 1 h at room tem-
perature, followed by incubation for 1 h with antibodies
for Stat3, Stat3 phospho-tyrosine 705, the cleaved form of
PARP, Bax and human β-actin. Blots were then washed
with PBS/0.05% Tween and incubated with horseradish
peroxidase-conjugated secondary antibody for 1 h at
room temperature, followed by an additional 3 washes
with PBS/0.05% Tween. Chemiluminescence detection
was performed according to the manufacturer's instruc-
tions (Amersham Life Sciences Inc., Piscataway, NJ) fol-
lowed by autoradiography.
Nuclear extracts were prepared from approximately 1 ×
107 cells. Briefly, cells were trypsinized and washed with
ice-cold PBS. Pelleted cells were resuspended in ice-cold
buffer A containing (10 mM HEPES pH 7.9, 10 mM KCl,
1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM PMSF, and 0.05%
NP-40). After centrifugation at 1,500 g for 3 min at 4°C
the pellet was resuspended in buffer C (20 mM HEPES,
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
DTT, 0.2 mM PMSF, and 25% (v/v) glycerol) for 30 min-
utes at 4°C, followed by centrifugation at 15,000 g for 20
min at 4°C. EMSA was performed with the Gel-Shift kit
(Cat No. AY1046, Panomics, Redwood, CA) according to
provided protocol. Briefly, nuclear extracts (3 µg) were
incubated with 10 ng biotin-labeled Stat3 response ele-
ment probe (5'-GATCCTTCTGGGAATTCCTAGATC-3')
derived from the c-fos gene promoter [52], in a binding
buffer (both provided in the kit, final volume of 10 µl)
containing 1 µg poly (dI-dC) for 40 min at 18°C. In the
competitive EMSA, nuclear extracts were incubated for 5
min at room temperature with 20 ng unlabeled probe
(provided by kit) prior to the addition of the biotin-
labeled probe. The reactions were loaded on a 6% polyacr-
ylamide non-denaturing PAGE gel in 0.5 × TBE buffer and
electrophoresed for 1.5 h at 150 V before being transferred
to BiodyneB membranes (PallGelman Lab, Ann Arbor,
MI) and detected by the reagents provided with the kit.
Cell viability and cell cycle assays
Cell viability was determined by the MTT (3- [4, 5-dimeth-
yltiazol 2-yl]-2,5-diphenyltetraolium) bromide assay
[53], essentially as previously described [54]. Briefly, cells
were plated in triplicate wells (1000 cells per well) in 100
µl growth media in 96-well plates and subjected to serum
starvation the following day, for the indicated durations.
At the appropriate times a solution of MTT (20 µl of a 12
mM solution in PBS) was added and incubated for 1 hour
at 37°C. The cells were washed gently with PBS, and 100
µl of dimethylsulfoxide was added to the wells followed
by mild shaking to dissolve the MTT precipitate. Absorb-
ance was measured for each well using a Wallac Victor3
1420 Multilabel multiwell plate reader (Perkin-Elmer) at
a wavelength of 540 nm. Mean absorbance values and
standard errors based on the mean (SEM) were calculated
for triplicate cultures. Cell doubling time was calculated
according to the following formula: doubling time (hrs) =
hrs in culture ÷ (log [A540F/A540I]/log2), where A540F
and A540I are the mean absorbance values of triplicate
cultures from the MTT assay at the end and beginning of
the time span measured, respectively. The cell cycle profile
of control and serum starved cells was determined by cell
cycle flow cytometry based on cellular DNA content,
using an FACSCalibur Cell Sorter (Becton Dickenson)
essentially as described previously [55]. Cells were serum-
starved for the indicated durations, trypsinized, collected
and pelleted together with the material floating in theMolecular Cancer 2006, 5:15 http://www.molecular-cancer.com/content/5/1/15
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medium. Cells were fixed in cold 70% ethanol, resus-
pended in PBS at a density of > 106 cells/ml followed by
RNase A (1 mg/ml) treatment, addition of propidium
iodide (20 µg/ml final concentration) and analysis by
flow cytometry. The percentage of cells at different phases
of the cell cycle was determined from the raw data using
the ModFit LT v 3.0 software package (Verity Software
House Inc.).
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media; DMEM, Dulbecco's Modified Eagles Media; FCS,
fetal calf serum; NHEK, normal human epidermal kerati-
nocytes; hEGF, human epidermal growth factor; IFN-α,
recombinant human interferon alpha; c-PARP, cleaved
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